Alcidion (ASX:ALC) Wins $7.5M Northern Care Alliance Contract to Roll Out Miya Flow Across Four NHS Hospitals

Sonal Goyal

30 September 2026 01:02 PM AEST

Alcidion (ASX:ALC) Wins $7.5M Northern Care Alliance Contract to Roll Out Miya Flow Across Four NHS Hospitals

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• Alcidion signed a new contract with Northern Care Alliance NHS Foundation Trust valued at $7.5 million over an initial three-year term.

• The contract upgrades the existing ExtraMed Flow product at Salford Royal Hospital to Miya Flow and expands to additional NCA sites.

• In-year Revenue expected to be recognised is approximately $4.5 million, including a six-month ExtraMed subscription renewal.

• Miya Flow will be deployed across Salford Royal, Royal Oldham, Fairfield General, and Rochdale Infirmary hospitals.

Alcidion Group Limited (ASX:ALC), a healthcare technology company with operations across Australia, New Zealand, and the United Kingdom, announced on 30 September 2026 that it has signed a new contract with Northern Care Alliance NHS Foundation Trust (NCA) in north-west England. The agreement, valued at a Total Contract Value (TCV) of $7.5 million over an initial three-year term, covers the deployment of Alcidion's Miya Flow patient flow management solution across the NCA trust. All values are in Australian dollars converted at an AUD/GBP rate of 0.52.

About Alcidion

Alcidion Group is a healthcare IT company listed on the ASX since 2016. Its flagship product, Miya Precision, aggregates clinical and operational data to support patient flow management, interoperability, and clinical decision-making in hospital environments. The company acquired ExtraMed in 2021, which had been providing patient flow software to NHS trusts. Alcidion operates across Australia, New Zealand, and the United Kingdom, serving hospitals and healthcare organisations in each market.

Contract Details and Revenue Recognition

The NCA contract expands Alcidion's existing relationship with the trust, which had been using the ExtraMed Flow product at Salford Royal Hospital. Under the new agreement, Miya Flow will replace the ExtraMed system at Salford Royal and be extended to additional sites within the NCA, including Royal Oldham Hospital, Fairfield General Hospital, and Rochdale Infirmary — four hospitals in total.

The initial term is three years, with Options to extend for a further two years and to expand the scope to include additional modules. The company indicated that in-year revenue expected to be recognised is approximately $4.5 million, which includes a six-month renewal of the ExtraMed subscription during the implementation period as Miya Flow is deployed across the trust.

Significance of the NCA Relationship

NCA is described as one of north-west England's largest healthcare trusts, providing hospital and community healthcare services across Greater Manchester. Its selection of Miya Flow over the continuation of ExtraMed — a product Alcidion itself owns — indicates the company's ability to upsell and upgrade existing customers to higher-value solutions.

Kate Quirke, Managing Director and CEO of Alcidion, cited the company's position as a leader in patient flow in UK and ANZ markets and noted that the expanded agreement will support operational efficiency across multiple sites by addressing challenges including bed blockages, patient outliers, and administrative burden.

UK Market Position

The UK National Health Service represents a significant addressable market for patient flow and clinical decision support software, given the scale and complexity of NHS operations. Alcidion's ability to convert an existing ExtraMed NHS customer into a Miya Flow contract adds revenue while demonstrating the commercial pathway available from its 2021 ExtraMed acquisition. The deal also adds contracted recurring revenue, which supports Alcidion's software subscription model.

Key Takeaways

Alcidion's new NCA contract adds $7.5 million in TCV to its UK healthcare IT pipeline and demonstrates the company's ability to upgrade existing NHS relationships to its flagship Miya Flow platform. The in-year revenue recognition of approximately $4.5 million, including the transitional ExtraMed renewal, provides near-term financial visibility. The deployment across four NCA hospitals will serve as a practical reference case for the Miya Flow platform within the UK NHS environment.

FAQs

Q: What is the Northern Care Alliance NHS contract announced by Alcidion?

A: Alcidion signed a $7.5 million, three-year contract with Northern Care Alliance NHS Foundation Trust to deploy Miya Flow across four hospitals, replacing the existing ExtraMed patient flow system.

Q: How much revenue does Alcidion expect to recognise in-year from this contract?

A: The company expects to recognise approximately $4.5 million in-year, which includes a six-month renewal of the ExtraMed subscription during the Miya Flow implementation period.

Q: What is Miya Flow?

A: Miya Flow is Alcidion's patient flow management solution, designed to reduce hospital operational friction such as bed blockages and excessive administrative burden, and is part of the broader Miya Precision product suite.

Q: Which hospitals are covered by the NCA contract?

A: Miya Flow will be deployed at Salford Royal Hospital, Royal Oldham Hospital, Fairfield General Hospital, and Rochdale Infirmary — all within the Northern Care Alliance NHS Foundation Trust.

Q: Why is this contract significant for Alcidion?

A: The contract demonstrates Alcidion's ability to upgrade existing NHS ExtraMed customers to Miya Flow, adding contracted recurring revenue and expanding its UK NHS footprint across a major trust.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.